1. Show article details.

    Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015

    GlobeNewswire – 4:05 PM ET 07/28/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, August 5, 2015 at 8:00 a.m. ET to discuss its second quarter 2015 financial results and provide a review of the Auryxia™ launch.

  2. Show article details.

    Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer

    GlobeNewswire – 8:00 AM ET 07/27/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the appointment of Scott A. Holmes to Chief Financial Officer effective immediately. "I am delighted to have Scott join Keryx at this stage of our company's development," said Greg Madison, chief executive officer of Keryx.

  3. Show article details.

    Keryx Receives CHMP Positive Opinion for Fexeric(R) (Ferric Citrate Coordination Complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease

    GlobeNewswire – 7:10 AM ET 07/24/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of ferric citrate coordination complex recommending approval for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease.

  4. Show article details.

    Keryx Announces Two National Insurance Providers Added Auryxia(TM) to Their Medicare Part D Formularies

    GlobeNewswire – 8:00 AM ET 06/24/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that two national insurance providers have added Auryxia™ to their Medicare Part D formularies.

  5. Show article details.

    Keryx Biopharmaceuticals to Present at the JMP Securities Life Sciences Conference 2015

    GlobeNewswire – 9:00 AM ET 06/16/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 24, 2015 at 2:30 p.m. EDT.

  6. Show article details.

    CORRECTING and REPLACING -- Keryx Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference

    GlobeNewswire – 6:32 PM ET 05/12/2015

    In the press release issued on May 5, 2015 by Keryx Biopharmaceuticals, Inc. (KERX) under the same headline, please note that the May 13th presentation falls on a Wednesday, not Thursday as originally stated.

  7. Show article details.

    Keryx Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference

    GlobeNewswire – 4:30 PM ET 05/05/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that Greg Madison, the Company's Chief Executive Officer, will be presenting a company overview, including progress with the commercialization of Auryxia™ in the United States, at the Bank of America Merrill Lynch 2015 Health Care Conference, to be held at the Encore at the Wynn in Las Vegas, NV on May 12-14, 2015.

  8. Show article details.

    Keryx Biopharmaceuticals Announces First Quarter 2015 Financial Results

    GlobeNewswire – 7:15 AM ET 05/04/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced its financial results for the first quarter ended March 31, 2015.

  9. Show article details.

    Keryx Biopharmaceuticals Completes Transition of CEO Role to Greg Madison

    GlobeNewswire – 4:30 PM ET 04/30/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced the completion of the previously announced transition of the CEO role from Ron Bentsur to Greg Madison.

  10. Show article details.

    Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2015 Financial Results

    GlobeNewswire – 4:30 PM ET 04/27/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that a conference call will be held on Monday, May 4th, 2015 at 8:00 a.m. ET to discuss financial results for the first quarter 2015 and provide an update on the Auryxia™ launch.

  11. Show article details.

    Keryx Biopharmaceuticals Appoints John F. Neylan, MD, as Chief Medical Officer

    GlobeNewswire – 8:00 AM ET 04/23/2015

    Keryx Biopharmaceuticals, Inc. (KERX), today announced the appointment of John F. Neylan, MD to the newly created position of Chief Medical Officer. "It is my pleasure to welcome John to Keryx," said Greg Madison, President and Chief Operating Officer of Keryx. "I am honored to be joining an organization so clearly dedicated to improving the lives of those with kidney disorders," said Dr. Neylan.

  12. Show article details.

    Keryx Biopharmaceuticals Announces Appointment of Greg Madison to Its Board of Directors

    GlobeNewswire – 4:55 PM ET 03/10/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the appointment of Mr. Greg Madison, the Company's President and Chief Operating Officer and incoming Chief Executive Officer, to its Board of Directors, effective March 10, 2015.

  13. Show article details.

    Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal of the American Society of Nephrology

    GlobeNewswire – 7:45 AM ET 03/04/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced the publication of Auryxia™ data and expert analyses in two peer-reviewed journals. The publication in JASN, titled "Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD" was led by Kausik Umanath, MD, Division of Nephrology and Hypertension at Henry Ford Hospital.

  14. Show article details.

    Keryx Announces Fourth Quarter and Year-End 2014 Financial Results

    GlobeNewswire – 7:00 AM ET 02/27/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced its financial results for the fourth quarter and year ended December 31, 2014. Ron Bentsur, the Company's Chief Executive Officer, commented, "I am very proud of the entire Keryx team and all that we have accomplished.

  15. Show article details.

    Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences

    GlobeNewswire – 4:10 PM ET 02/25/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that corporate presentations will be delivered at the following upcoming investor conferences: Cowen and Company 35th Annual Health Care Conference Presenter: Greg Madison, President and Chief Operating Officer Presentation Date: Monday, March 2nd, 2015 Presentation Time: 4:50 pm ET.

  16. Show article details.

    Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial Results

    GlobeNewswire – 8:00 AM ET 02/18/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that a conference call will be held on Friday, February 27th, 2015 at 8:00 a.m. ET to discuss financial results for the fourth quarter and year-ended 2014, and a business outlook for 2015.

Page:

Today's and Upcoming Events

  • Aug
    5

    KERX to announce Q2 earnings Before Market (Confirmed)

  • Aug
    5

    KERX Earnings Conference Call at 8:00 AM Listen

Past Events (last 90 days)

  • Jun
    16

    Shareholders Meeting

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.